For example, BRAF inhibitors have shown promising efficacy in BRAF-mutated lung and thyroid cancers as well as in hairy cell leukemia, indicating that oncogenic driver mutations do not necessarily segregate by histology, and matched molecular therapy is effective across many, but not all, histologies [8, 9, 10, 11, 12]. This evidence concerns the gene BRAF and thyroid cancer.